Summit Therapeutics SMMT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's accrued expenses?
- Summit Therapeutics (SMMT) reported accrued expenses of $7.07M in Q1 2026.
- How has Summit Therapeutics's accrued expenses changed year-over-year?
- Summit Therapeutics's accrued expenses increased by 60.9% year-over-year, from $4.4M to $7.07M.
- What is the long-term trend for Summit Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Summit Therapeutics's accrued expenses has grown at a 72.3% compound annual growth rate (CAGR), from $983K to $14.93M.
- What does accrued expenses mean?
- Expenses that have been incurred but are not yet due for payment.
- How do you interpret accrued expenses?
- Rising accruals can indicate growing operational activity or delayed billing cycles, while falling accruals may signal a reduction in operational commitments.
- How does accrued expenses compare across companies?
- Common in R&D-heavy companies where clinical trial costs are accrued over the duration of the study.